Inhibitors of adenosine 5′-nucleotidase
Compounds that modulate the conversion of AMP to adenosine by 5′-nucleotidase, ecto, and compositions containing the compounds and methods for synthesizing the compounds, are described herein. The use of such compounds and compositions for the treatment and/or prevention of a diverse array of diseases, disorders and conditions, including cancer- and immune-related disorders, that are mediated by 5′-nucleotidase, ecto is also provided.
1. A compound having the formula:
or a pharmaceutically acceptable salt, hydrate, or solvate thereof, wherein,
each R 1 is independently selected from the group consisting of hydrogen, optionally substituted C 1 -C 6 alkyl, optionally substituted aryl, —C(R 2 R 2 )—O—C(O)—OR 3 , C(R 2 R 2 )—O—C(O)R 3 , and —C(R 2 R 2 )C(O)OR 3 , or two R 1 groups are optionally combined to form a 5- to 6-membered ring;
each R 2 is independently selected from the group consisting of H and optionally substituted C 1 -C 6 alkyl;
each R 3 is independently selected from the group consisting of H, C 1 -C 6 alkyl, C 1 -C 6 alkoxyC 1 -C 6 alkyl, and optionally substituted aryl;
R 5 is selected from the group consisting of H and optionally substituted C 1 -C 6 alkyl;
X is O;
A is selected from the group consisting of:
each of which is optionally substituted with from 1 to 5 R 6 substituents;
Z is selected from the group consisting of CH 2 , CHR 6 , NH, NR 6 , and O;
each R 6 is independently selected from the group consisting of CH 3 , OH, CN, F, optionally substituted C 1 -C 6 alkyl, and OC(O)-C 1 -C 6 alkyl; or two R 6 groups on adjacent ring vertices are optionally joined together to form a 5- to 6-membered ring having at least one heteroatom as a ring vertex; and
Het is selected from the group consisting of:
wherein the wavy line indicates the point of attachment to the remainder of the compound, and wherein:
R a is selected from the group consisting of NHR 7 , NR 7 R 7 , R 7 , SR 7 and OR 7 ;
R b is selected from the group consisting of H, halogen, NH 2 , NHR 7 , NR 7 R 7 , R 7 , OH, and OR 7 ;
R c and R d are independently selected from the group consisting of H, halogen, haloalkyl, NH 2 , NHR 7 , NR 7 R 7 , R 7 , OH, OR 7 , SW, SO 2 R 7 , —X 1 —NR 7 R 7 , —X 1 —OR 7 , —X 1 —SR 7 and -X 1 —SO 2 R 7 ;
R e and R f are independently selected from the group consisting of H, halogen, and optionally substituted C 1 -C 6 alkyl;
each X 1 is C 1 -C 4 alkylene; and
each R 7 is independently selected from the group consisting of optionally substituted C 1 -C 10 alkyl, optionally substituted C 2 -C 10 alkenyl, optionally substituted C 2 -C 10 alkynyl, optionally substituted C 3 -C 7 cycloalkyl, optionally substituted C 3 -C 7 cycloalkylC 1 -C 4 alkyl, optionally substituted 4-7 membered cycloheteroalkyl, optionally substituted 4-7 membered cycloheteroalkylC 1 -C 4 alkyl, optionally substituted aryl, optionally substituted arylC 1 -C 4 alkyl, optionally substituted arylC 2 -C 4 alkenyl, optionally substituted arylC 2 -C 4 alkynyl, optionally substituted heteroaryl, optionally substituted heteroarylC 1 -C 4 alkyl, optionally substituted heteroarylC 2 -C 4 alkenyl, and optionally substituted heteroarylC 2 -C 4 alkynyl; or
when two R 7 groups attached to the same nitrogen atom, they are optionally joined together to form a 4- to 7-membered heterocyclic ring which is optionally fused to an aryl ring.
2. The compound of claim 1 , wherein each R 3 is independently selected from the group consisting of H, C 1 -C 6 alkyl, and optionally substituted aryl.
3. The compound of claim 1 , wherein A is:
which is optionally substituted with from 1 to 5 R 6 .
4. The compound of claim 1 , wherein A is selected from the group consisting of:
5. The compound of claim 1 , wherein Het is:
wherein each G is independently selected from the group consisting of N and CR e .
6. The compound of claim 1 , wherein Het has the formula:
7. The compound of claim 1 , wherein Het has the formula:
8. The compound of claim 1 , wherein Het has the formula:
9. The compound of claim 1 , wherein Het has the formula:
10. The compound of claim 1 , wherein Het has the formula:
11. The compound of claim 1 , wherein R c is other than hydrogen.
12. The compound of claim 1 , having a formula selected from the group consisting of:
wherein each R g is independently selected from the group consisting of H and C(O)-C 1 -C 6 alkyl; and each G is independently selected from the group consisting of N and CR e .
13. The compound of claim 1 , wherein R 5 is H, and each R 1 is H.
14. The compound of claim 1 , wherein Het is selected from
15. The compound of claim 14 , wherein R 5 is H, each R 1 is H, R e is H, R c is other than H, and R a is NHR 7 .
16. The compound of claim 1 , wherein R c is halogen.
17. The compound of claim 1 , wherein each R 7 is independently selected from the group consisting of optionally substituted C 1 -C 10 alkyl, optionally substituted C 3 -C 7 cycloalkyl, optionally substituted 4-7 membered cycloheteroalkyl, and optionally substituted arylC 1 -C 4 alkyl; or
when two R 7 groups attached to the same nitrogen atom, they are optionally joined together to form a 4- to 7-membered heterocyclic ring which is optionally fused to an aryl ring.
18. A pharmaceutical composition comprising a compound of claim 1 , or a pharmaceutically acceptable salt, hydrate, or solvate thereof, and a pharmaceutically acceptable excipient.
19. A method of treating a disease, disorder, or condition, mediated at least in part by CD73, said method comprising administering an effective amount of a compound of claim 1 , or a pharmaceutically acceptable salt, hydrate, or solvate thereof, to a subject in need thereof.
20. The method of claim 19 , wherein said disease, disorder, or condition is an immune-related disease, disorder or condition selected from the group consisting of rheumatoid arthritis, kidney failure, lupus, asthma, psoriasis, colitis, pancreatitis, allergies, fibrosis, anemia fibromyalgia, Alzheimer's disease, congestive heart failure, stroke, aortic valve stenosis, arteriosclerosis, osteoporosis, Parkinson's disease, infections, Crohn's disease, ulcerative colitis, allergic contact dermatitis and other eczemas, systemic sclerosis and multiple sclerosis.
21. A combination comprising a compound of claim 1 , or a pharmaceutically acceptable salt, hydrate, or solvate thereof, and at least one additional therapeutic agent.
22. A kit comprising a compound of claim 1 , or a pharmaceutically acceptable salt, hydrate, or solvate thereof, and at least one additional therapeutic agent.
23. A method of treating cancer in a subject, said method comprising administering to said subject an effective amount of a compound of claim 1 , or a pharmaceutically acceptable salt, hydrate, or solvate thereof, and an immune checkpoint inhibitor.
24. The method of claim 23 , wherein said immune checkpoint inhibitor is selected from the group consisting of ipulimumab, nivolumab, pembrolizumab, avelumab, atezolizumab, durvalumab and lambrolizumab.
25. A compound having a formula selected from the group consisting of